Rett syndrome is a serious and rare neurodevelopmental congenital CNS disorder with symptoms that typically present between six to 18 months of age, and lead to problems with
The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fever vaccine candidate. The phase 1 trial
Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid
The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – EAGLE-1 and EAGLE-2.
The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of Imfinzi
“The MAHOGANY study for patients with gastric or gastroesophageal junction cancer is designed to support registration of margetuximab and is a part of our strategy to advance margetuximab
Phase 1 study results showed escalating doses of TBC-1002 to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) symptoms. No systemic exposure or
Gilteritinib can be used in the treatment of AML patients whose disease is in the relapsed or refractory stage, and who express a FLT3 mutation (FLT3mut+). The oral
The BLA for ROLONTIS is supported by data from two identically designed Phase 3 clinical trials, ADVANCE and RECOVER, which evaluated the safety and efficacy of ROLONTIS in
RAPT is developing RPT193 initially for the treatment of atopic dermatitis, and subsequently plans to expand clinical development into allergic asthma and other allergic inflammatory diseases. “The onset
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.